These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 3315594)

  • 1. Assessment of left ventricular function in a randomised study of intravenous anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction. Preliminary results of the European Multicentre Study (Belgian Centres).
    Taeymans Y; Materne P
    Drugs; 1987; 33 Suppl 3():216-20. PubMed ID: 3315594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous anisoylated plasminogen streptokinase activator complex versus intravenous streptokinase in evolving myocardial infarction. Preliminary data from a randomised multicentre study.
    Brochier ML; Quilliet L; Kulbertus H; Materne P; Letac B; Cribier A; Monassier JP; Sacrez A; Favier JP
    Drugs; 1987; 33 Suppl 3():140-5. PubMed ID: 3315581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of coagulation and fibrinolysis after intravenous anisoylated plasminogen streptokinase activator complex or heparin in patients with acute myocardial infarction. A Belgian multicentre study.
    Renkin J; Beys CC; Lavenne-Pardonge E; Pintens H; Col J
    Drugs; 1987; 33 Suppl 3():253-60. PubMed ID: 3315603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anisoylated plasminogen streptokinase complex during the acute phase of myocardial infarction. Results of a multicenter double-blind study versus heparin].
    Cassagnes J; Bassand JP; Machecourt J; Lusson JR; Anguenot T; Borel E; Vacher D; Denis B; Maurat JP; Jallut H
    Arch Mal Coeur Vaiss; 1990 Apr; 83(4):453-60. PubMed ID: 2111665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reperfusion in acute myocardial infarction. A multicentre randomised trial of early intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in the United States.
    Anderson JL
    Drugs; 1987; 33 Suppl 3():154-62. PubMed ID: 3315584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: effects on infarct size and left ventricular function.
    Bassand JP; Machecourt J; Cassagnes J; Anguenot T; Lusson R; Borel E; Peycelon P; Wolf E; Ducellier D
    J Am Coll Cardiol; 1989 Apr; 13(5):988-97. PubMed ID: 2647817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects on infarct size and left ventricular function of early intravenous injection of anistreplase in acute myocardial infarction. The APSIM Study Investigators.
    Bassand JP; Bernard Y; Lusson JR; Machecourt J; Cassagnes J; Borel E
    Clin Cardiol; 1990 Mar; Suppl 5():V39-44; discussion V67-72. PubMed ID: 2182240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction.
    Meinertz T; Kasper W; Schumacher M; Just H
    Am J Cardiol; 1988 Sep; 62(7):347-51. PubMed ID: 3046283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase.
    Anderson JL; Rothbard RL; Hackworthy RA; Sorensen SG; Fitzpatrick PG; Dahl CF; Hagan AD; Browne KF; Symkoviak GP; Menlove RL
    J Am Coll Cardiol; 1988 Jun; 11(6):1153-63. PubMed ID: 3284943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A placebo-controlled patency study of intravenous anisoylated plasminogen streptokinase activator complex 30U in acute myocardial infarction.
    de Bono DP
    Drugs; 1987; 33 Suppl 3():138-9. PubMed ID: 3315580
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and tolerance data from the Belgian multicentre study of anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction.
    Bossaert LL
    Drugs; 1987; 33 Suppl 3():287-92. PubMed ID: 3315610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anisoylated plasminogen streptokinase activator complex versus placebo. A preliminary multicentre study of safety and early mortality in acute myocardial infarction.
    Julian DG; Borthwick LS; Reid D; Jennings KP; Wainwright RJ; Rodger JC; Wood D; Phillips WS
    Drugs; 1987; 33 Suppl 3():261-7. PubMed ID: 3315604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of intravenous anisoylated plasminogen streptokinase activator complex with intracoronary streptokinase in acute myocardial infarction.
    Bonnier JJ
    Drugs; 1987; 33 Suppl 3():151-3. PubMed ID: 3315583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anisoylated plasminogen streptokinase activator complex versus streptokinase in acute myocardial infarction. Preliminary results of a randomised study.
    Monnier P; Sigwart U; Vincent A; Bachmann F; Goy JJ; Schaller MD; Kaufmann U; Badan M; Grbic M; Perret C
    Drugs; 1987; 33 Suppl 3():175-8. PubMed ID: 3315587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of 2 intravenous thrombolytic agents (anisoylated plasminogen streptokinase activator complex versus streptokinase) in patients with acute myocardial infarction.
    Seabra-Gomes R; Aniceto Silva J; Aleixo A; Real T; Freire I; Torres I; Freitas R; Crespo F
    Drugs; 1987; 33 Suppl 3():169-74. PubMed ID: 3315586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracoronary streptokinase versus intravenous anisoylated plasminogen streptokinase activator complex in the treatment of acute myocardial infarction.
    Kaspar L; Karnik R; Sehnal E; Zajicek P; Ziegler B; Slany J
    Drugs; 1987; 33 Suppl 3():179-82. PubMed ID: 3315588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AIMS. The design and conduct of a multicentre mortality study comparing placebo and anisoylated plasminogen streptokinase activator complex 30 units intravenously for the treatment of acute myocardial infarction of less than 6 hours duration. UK APSAC Advisory Committee.
    Drugs; 1987; 33 Suppl 3():227-8. PubMed ID: 3315598
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction.
    Bonnier HJ; Visser RF; Klomps HC; Hoffmann HJ
    Am J Cardiol; 1988 Jul; 62(1):25-30. PubMed ID: 3289357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrocardiographic and enzymatic infarct size in a randomised study of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
    Hackworthy RA; Sorensen SG; Menlove RL; Anderson JL
    Drugs; 1987; 33 Suppl 3():198-208. PubMed ID: 3315592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of myocardial defect size measured by thallium-201 SPECT: results of a multicenter trial comparing heparin and a new fibrinolytic agent.
    Maublant JC; Peycelon P; Cardot JC; Verdenet J; Fagret D; Comet M
    J Nucl Med; 1988 Sep; 29(9):1486-91. PubMed ID: 3045271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.